FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
PAVmed Inc. Stock AnalysisComprehensive stock analysis for PAVmed Inc. (PAVMW) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisPAVMW
PAVMW
PAVmed Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
PAVMW
Home🔹Stocks🔹PAVmed Inc.

PAVmed Inc.

PAVMW•NASDAQ

PAVmed Inc.

PAVMW•NASDAQ
Sentiment

Your view on PAVMW

Sentiment
Your view
PAVMW
PAVmed Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
PAVMW
Company Overview

Overview

What the company does, where it operates, and who runs it.

About PAVmed Inc.

Industry
Medical - Devices
Sector
Healthcare
CEO
Lishan Aklog
Headquarters
One Grand Central Place, New York City, NY, US
Industry
Medical - Devices
Sector
Healthcare
CEO
Lishan Aklog
Headquarters
One Grand Central Place, New York City, NY, US
Description

PAVmed Inc. is a U.S.-based company that develops and commercializes innovative medical technologies. Its core product offerings include CarpX, a minimally invasive device designed for treating carpal tunnel syndrome, and EsoCheck, an advanced system for collecting esophageal cells to aid in the early identification of esophageal adenocarcinoma and Barrett's Esophagus (BE). The company's robust development pipeline further encompasses EsoGuard, a molecular diagnostic test utilizing esophageal DNA; EsoCure, an ablation device targeting dysplastic BE; PortIO, an implantable solution for intraosseous vascular access; NextFlo, a disposable infusion platform; and DisappEAR, a resorbable ear tube for pediatric use. Additional projects in their portfolio include NextCath and Caldus. Established in 2014 and headquartered in New York, New York, the firm initially operated under the name PAXmed Inc. before rebranding as PAVmed Inc. in April 2015.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News